The genetics of hereditary melanoma and nevi: 1998 Update

Cancer

Volumn 86, Issue 8 SUPPL., 1999, Pages 1644-1657

  Greene, Mark H ^a,b  

^a MAYO CLINIC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CDK4; CDKN2A; Dysplastic nevi; Hereditary melanoma; Melanoma astrocytoma syndrome

Indexed keywords

CYCLIN DEPENDENT KINASE;

ADULT; ASTROCYTOMA; CANCER GENETICS; CANCER RISK; CARCINOGENESIS; CLINICAL FEATURE; CONFERENCE PAPER; DISEASE ASSOCIATION; DYSPLASIA; FAMILIAL CANCER; FEMALE; GENE LOCUS; GENE MAPPING; GENE MUTATION; HUMAN; MALE; MELANOMA; PATHOGENESIS; PRIORITY JOURNAL; SKIN EXAMINATION;

EID: 0033569978     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(19991015)86:8+<1644::aid-cncr3>3.0.co;2-s     Document Type: Conference Paper

References (123)

1. Norris W. Case of fungoid disease. Edinburgh Med Surg J 1820;16:562-5.
2. Cawley EP. Genetic aspects of malignant melanoma. Arch Dermatol Syph 1952;65:440-50.
3. Greene MH, Fraumeni JF Jr. The hereditary variant of malignant melanoma. In: Human malignant melanoma. Clark WH Jr, Goldman LI, Mastrangelo MJ, editors. New York: Grune & Stratton, 1979:139-66.
4. Grange F, Chompret A, Guilloud-Bataille M, Guillaume JC, Margulis A, Prade M, et al. Comparison between familial and nonfamilial melanoma in France. Arch Dermatol 1995; 131:1154-9.
5. Ang CG, Kelly JW, Fritschi L. Characteristics of familial and nonfamilial melanoma in Australia. Melanoma Res, in press.
6. Ford D, Bliss JM, Swerdlow AJ, Armstrong BK, Franceschi S, Green A, et al. Risk of cutaneous melanoma associated with a family history of the disease. Int J Cancer 1995;62:377-81.
7. Reimer RR, Clark WH Jr, Greene MH, Ainsworth AM, Fraumeni JF Jr. Precursor lesions in familial melanoma. A new genetic preneoplastic syndrome. JAMA 1978;239:744-6.
8. Clark WH Jr, Reimer RR, Greene M, Ainsworth AM, Mastrangelo MJ. Origin of familial malignant melanomas from heritable melanocytic lesions. "The B-K mole syndrome." Arch Dermatol 1978;114:732-8.
9. Greene MH, Clark WH Jr, Tucker MA, Kraemer KH, Elder DE, Fraser MC. High risk of malignant melanoma in melanoma-prone families with dysplastic nevi. Ann Intern Med 1985;102:458-65.
10. Greene MH, Clark WH Jr, Tucker MA, Elder DE, Kraemer KH, Guerry D IV, et al. Acquired precursors of cutaneous malignant melanoma. The familial dysplastic nevus syndrome. N Engl J Med 1985;312:91-7.
11. Greene MH, Goldin LR, Clark WH Jr, Lovrien E, Kraemer KH, Tucker MA, et al. Familial cutaneous malignant melanoma: autosomal dominant trait possibly linked to the Rh locus. Proc Natl Acad Sci USA 1983;80:6071-5.
12. Lynch HT, Fusaro RM, Kimberling WJ, Lynch JF, Danes BS. Familial atypical multiple mole-melanoma (FAMMM) syndrome: segregation analysis. J Med Genet 1983;20:342-4.
13. Bale SJ, Chakravarti A, Greene MH. Cutaneous malignant melanoma and familial dysplastic nevi: evidence for autosomal dominance and pleiotropy. Am J Hum Genet 1986;38: 188-96.
14. Risch N, Sherman S. Genetic Analysis Workshop 7: summary of the melanoma workshop. Cytogenet Cell Genet 1992;59: 148-58.
15. Bale SJ, Dracopoli NC, Tucker MA, Clark WH Jr, Fraser MC, Stanger BZ, et al. Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. N Engl J Med 1989;320:1367-72.
16. Goldstein AM, Dracopoli NC, Ho EC, Fraser MC, Kearns KS, Bale SJ, et al. Further evidence for a locus for cutaneous malignant melanoma-dysplastic nevus (CMM/DN) on chromosome 1p, and evidence for genetic heterogeneity. Am J Hum Genet 1993;52:537-50.
17. Tucker MA, Fraser MC, Goldstein AM, Elder DE, Guerry D IV, Organic SM. Risk of melanoma and other cancers in melanoma-prone families. J Invest Dermatol 1993;100:350S-5S.
18. van Haeringen A, Bergman W, Nelen MR, van der Kooij-Meijs E, Hendrikse I, Wijnen JT, et al. Exclusion of the dysplastic nevus syndrome (DNS) locus from the short arm of chromosome 1 by linkage studies in Dutch families. Genomics 1989;5:61-4.
19. Cannon-Albright LA, Goldgar DE, Wright EC, Turco A, Jost M, Meyer LJ, et al. Evidence against the reported linkage of the cutaneous melanoma-dysplastic nevus syndrome locus to chromosome 1p36. Am J Hum Genet 1990;46:912-8.
20. Kefford RF, Salmon J, Shaw HM, Donald JA, McCarthy WH. Hereditary melanoma in Australia. Variable association with dysplastic nevi and absence of genetic linkage to chromosome 1p. Cancer Genet Cytogenet 1991;51:45-55.
21. Nancarrow DJ, Palmer JM, Walters MK, Kerr BM, Hafner GJ, Garske L, et al. Exclusion of the familial melanoma locus (MLM) from the PND/D1S47 and MYCL1 regions of chromosome arm 1p in 7 Australian pedigrees. Genomics 1992; 12:18-25.
22. Bergman W, Gruis NA, Sandkuijl LA, Frants RR. Genetics of seven Dutch familial atypical multiple mole-melanoma syndrome families: a review of linkage results including chromosomes 1 and 9. J Invest Dermatol (suppl 5) 1994;103: 122S-5S.
23. Cowan JM, Halaban R, Francke U. Cytogenetic analysis of melanocytes from premalignant nevi and melanomas. J Natl Cancer Inst 1988;80:1159-64.
24. Fountain JW, Karayiorgou M, Graw SL, Buckler AJ, Taruscio D, Ward DC, et al. Chromosome 9p involvement in melanoma (abstract). Am J Hum Genet 1991;49:45.
25. Petty EM, Bolognia JL, Bale AE, Yang-Feng T. Cutaneous malignant melanoma and atypical moles associated with a constitutional rearrangement of chromosomes 5 and 9. Am J Med Genet 1993;45:77-80.
26. Cannon-Albright LA, Goldgar DE, Meyer LJ, Lewis CM, Anderson DE, Fountain JW, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992;258:1148-52.
27. Cannon-Albright LA, Goldgar DE, Neuhausen S, Gruis NA, Anderson DE, Lewis CM, et al. Localization of the 9p melanoma susceptibility locus (MLM) to a 2-cM region between D9S736 and D9S171. Genomics 1994;23:265-8.
28. Cannon-Albright LA, Meyet LJ, Goldgar DE, Lewis CM, McWhorter WP, Jost M, et al. Penetrance and expressivity of the chromosome 9p melanoma susceptibility locus (MLM). Cancer Res 1994;54:6041-4.
29. Battistutta D, Palmer J, Walters M, Walker G, Nancarrow D, Hayward N. Incidence of familial melanoma and MLM2 gene. Lancet 1994;344:1607-8.
30. Goldstein Am, Falk RT, Fraser MC, Dracopoli NC, Sikorski RS, Clark WH Jr, et al. Sun-related risk factors in melanoma prone families with CDKN2A mutations. J Natl Cancer Inst 1998;90:709-11.
31. Nancarrow DJ, Mann GJ, Holland EA, Walker GJ, Beaton SC, Walters MK, et al. Confirmation of chromosome 9p linkage in familial melanoma. Am J Hum Genet 1993;53:936-42.
32. Gruis NA, Sandkuijl LA, Weber JL, van der Zee A, Borgstein AM, Bergman W, et al. Linkage analysis in Dutch familial atypical multiple mole-melanoma (FAMMM) syndrome families. Effect of naevus count. Melanoma Res 1993; 3:271-7.
33. MacGeoch C, Bishop JA, Bataille V, Bishop DT, Frischauf AM, Meloni R, et al. Genetic heterogeneity in familial malignant melanoma. Hum Mol Genet 1994;3:2195-2200.
34. Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994;264:436-40.
35. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, et al. Germline p16 mutations in familial melanoma. Nat Genet 1994;8:15-21.
36. INK4 function. Nat Genet 1995;10: 114-6.
37. Kamb A, Shattuck-Eidens D, Eeles R, Liu Q, Gruis NA, Ding W, et al. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat Genet 1994;8:22-26.
38. Haluska FG, Hodi FS. Molecular genetics of familial cutaneous melanoma. J Clin Oncol 1998;16: 670-82.
39. Quelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995;83:993-1000.
40. ARF and CDK4 in familial melanoma. Proc Natl Acad Sci USA 1996;93:8541-5.
41. Platz A, Hansson J, Monsson-Brahme E, Lagerlof B, Linder S, Lundqvist E, et al. Screening of germline mutations in CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma. J Natl Cancer Inst 1997;89: 697-702.
42. Hayward N, Flores J, Polloch P, Walker G, Glendening JM, Lin A, et al. Analysis of CDKN2A, CDKN2B and CDK4 genes in 48 Australian melanoma kindreds. Melanoma Res (suppl 1) 1997;7:S37.
43. Greene MH, Tucker MA, Clark WH Jr, Kraemer KH, Elder DE, Fraser MC. Hereditary melanoma and the dysplastic nevus syndrome: the risk of cancers other than melanoma. J Am Acad Dermatol 1987;16:792-7.
44. Lynch HT, Fusaro RM, Pester J, Oosterhuis JA, Went LN, Rumke P, et al. Tumour spectrum in the FAMMM syndrome. Br J Cancer 1981;44:553-60.
45. Bergman W, Watson P, de long J, Lynch HT, Fusaro RM. Systemic cancer and the FAMMM syndrome. Br J Cancer 1990;61:932-6.
46. Schenk M, Severson RK, Pawlish KS. The risk of subsequent primary carcinoma of the pancreas in patients with cutaneous malignant melanoma. Cancer 1998;82:1672-6.
47. INK4 mutations. N Engl J Med 1995;333:970-4.
48. Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med 1995;333:975-7.
49. Monzon J, Liu L, Brill H, Goldstein AM, Tucker MA, From L, et al. CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998;338:879-87.
50. INK4a in sensitive CDK4 mutant targeted by cytolytic T-cells in a human melanoma. Science 1995;269:1281-4.
51. INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12: 97-9.
52. Bressac-de Paillerets B, Soufir N, Chompret A, Bombled J, Demenais F, Spatz A, et al. Germline mutations in p16 and CDK4 genes in 38 melanoma families. Melanoma Res 1997; 7:S132.
53. Kaufman DK, Kimmel DW, Parisi JE, Michels VY. A familial syndrome with cutaneous melanoma and cerebral astrocytoma. Neurology 1993;43:1728-31.
54. Bahuau M, Vidaud D, Kujas M, Palangie A, Assouline B, Chaignaud-Lebreton M, et al. Familial aggregation of malignant melanoma/dysplastic nevi and tumors of the central nervous system - an original syndrome of tumor proneness. Ann Genet 1997;4:78-91.
55. Azizi E, Friedman J, Pavlotsky J, Iscovich J, Bornstein A, Shafir R, et al. Familial cutaneous melanoma and tumors of the central nervous system. Cancer 1995;76:1571-8.
56. Bahuau M, Vidaud D, Jenkins RB, Bieche I, Kimmel DW, Assouline B, et al. Germline deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res 1998;58:2298-2303.
57. Bale SJ, Greene MH, Murray C, Goldin LR, Johnson AH, Mann D. Hereditary malignant melanoma is not linked to the HLA complex on chromosome 6. Int J Cancer 1985;36: 439-43.
58. Walker GJ, Nancarrow DJ, Walters MK, Palmer JM, Weber JL, Hayward NK. Linkage analysis in familial melanoma kindreds to markers on chromosome 6p. Int J Cancer 1994;59: 771-5.
59. Albino AP. Genes involved in melanoma susceptibility and progression. Curr Opin Oncol 1995;7:162-9.
60. Easton DF, Cox GM, Macdonald AM, Ponder BA. Genetic susceptibility to naevi - a twin study. Br J Cancer 1991;64: 1164-7.
61. Goldgar DE, Cannon-Albright LA, Meyer LJ, Piepkorn MW, Zone JJ, Skolnick MH. Inheritance of nevus number and size in melanoma and dysplastic nevus syndrome kindreds. J Natl Cancer Inst 1991;83:1726-33.
62. Newton Bishop JA, Bataille V, Pinney E, Bishop DT. Family studies in melanoma: identification of the atypical mole syndrome (AMS) phenotype. Melanoma Res 1994;4:199-206.
63. Maiweg C, Gartmann H, Lippold A, Balkau D, Wischer W, Suter L. The usefulness of single and combined clinical characteristics for the diagnosis of dysplastic naevi. Melanoma Res 1992;1:377-83.
64. Duray PH, DerSimonian R, Barnhill R, Stenn K, Ernstoff MS, Fine J, et al. An analysis of interobserver recognition of the histopathologic features of dysplastic nevi from a mixed group of nevomelanocytic lesions. J Am Acad Dermatol 1992;27:741-9.
65. Smoller BR, Egbert BM. Dysplastic nevi can be diagnosed and graded reproducibly: a longitudinal study. J Am Acad Dermatol 1992;27:399-402.
66. de Wit PE, van't Hof-Grootenboer B, Ruiter DJ, Bondi R, Brocker EB, Cesarini JP, et al. Validity of the histopathological criteria used for diagnosing dysplastic naevi. An interobserver study by the pathology subgroup of the EORTC Malignant Melanoma Cooperative Group. Eur J Cancer 1993;29A:831-9.
67. Duncan LM, Berwick M, Bruijn JA, Byers HR, Mihm MC, Barnhill RL. Histopathologic recognition and grading of dysplastic melanocytic nevi: an interobserver agreement study. J Invest Dermatol 1993;100:318S-21S.
68. Piepkorn MW, Barnhill RL, Cannon-Albright LA, Elder DE, Goldgar DE, Lewis CM, et al. A multiobserver, population-based analysis of histologic dysplasia in melanocytic nevi. J Am Acad Dermatol 1994;30:707-14.
69. Hastrup N, Clemmensen OJ, Spaun E, Sondergaard K. Dysplastic naevus: histological criteria and their inter-observer reproducibility. Histopathology 1994;24:503-9.
70. Tucker MA, Halpern A, Holly EA, Hartge P, Elder DE, Sagebiel RW, et al. Clinically recognized dysplastic nevi - a central risk factor for cutaneous melanoma. JAMA 1997;277: 1439-44.
71. Crutcher WA, Sagebiel RW. Prevalence of dysplastic naevi in a community practice (letter). Lancet 1984;1:729.
72. Tucker MA, Crutcher WA, Hartge P, Sagebiel RW. Familial and cutaneous features of dysplastic nevi: a case-control study. J Am Acad Dermatol 1993;28:558-64.
73. Goldstein AM, Tucker MA, Crutcher WA, Hartge P, Sagebiel RW. The inheritance pattern of dysplastic naevi in families of dysplastic naevus patients. Melanoma Res 1993;3:15-22.
74. Crijns MB, Vink J, Van Hees CL, Bergman W, Vermeer BJ. Dysplastic nevi. Occurrence in first-and second-degree relatives of patients with "sporadic" dysplastic nevus syndrome. Arch Dermatol 1991;127:1346-51.
75. Bataille V, Grulich A, Sasieni P, Swerdlow A, Bishop JN, McCarthy W, et al. The association between naevi and melanoma in populations with different levels of sun exposure. Br J Cancer 1998;77:505-10.
76. Newton JA, Bataille V, Griffiths K, Squire JM, Sasieni P, Cuzick J, et al. How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? J Am Acad Dermatol 1993;29:989-96.
77. Puig S, Ruiz A, Castel T, Volpini V, Malveky J, Cardellach F, et al. Inherited susceptibility to several cancers but absence of linkage between dysplastic nevus syndrome and CDKN2A in a melanoma family with a CDKN2A mutation. Hum Genet 1997;101:359-64.
78. Park WS, Vortmeyer AO, Pack S, Duray P, Boni R, Guerami AA, et al. Allelic deletion at chromosome 9p21 (p16) and 17p13 (p53) in microdissected sporadic dysplastic nevus. Hum Pathol 1998;29:127-30.
79. Nordlund JJ, Kirkwood J, Forget BM, Scheibner A, Albert DM, Lerner E, et al. Demographic study of clinically atypical (dysplastic) nevi in patients with melanoma and comparison subjects. Cancer Res 1985;45:1855-61.
80. Cristofolini M, Franceschi S, Tasin L, Zumiani G, Piscioli F, Talamini R, et al. Risk factors for cutaneous malignant melanoma in a northern Italian population. Int J Cancer 1987; 39:150-4.
81. Swerdlow AJ, English J, MacKie RM, O'Doherty CJ, Hunter JA, Clark J, et al. Benign melanocytic naevi as a risk factor for malignant melanoma. BMJ 1986;292:1555-9.
82. Roush GC, Nordlund JJ, Forget B, Gruber SB, Kirkwood JM. Independence of dysplastic nevi from total nevi in determining risk for nonfamilial melanoma. Prev Med 1988;17: 273-9.
83. Kelly JW, Holly EA, Shpall SN, Ahn DK. The distribution of melanocytic naevi in melanoma patients and control subjects. Australas J Dermatol 1989;30:1-8.
84. Grob JJ, Gouvernet J, Aymar D, Mostaque A, Romano MH, Collet AM, et al. Count of benign melanocytic nevi as a major indicator of risk of nonfamilial nodular and superficial spreading melanoma. Cancer 1990;66:387-95.
85. Halpern AC, Guerry D IV, Elder DE, Clark WH Jr, Synnestvedt M, Norman S, et al. Dysplastic nevi as risk markers of sporadic (nonfamilial) melanoma. A case-control study. Arch Dermatol 1991;127:995-9.
86. Stierner U, Augustsson A, Rosdahl I, Suurkula M. Regional distribution of common and dysplastic naevi in relation to melanoma site and sun exposure. A case-control study. Melanoma Res 1992;1:367-75.
87. Garbe C, Büttner P, Weiss J, Soyer HP, Stocker U, Krüger S, et al. Risk factors for developing cutaneous melanoma and criteria for identifying persons at risk: multicenter case-control study of the central malignant melanoma registry of the German Dermatological Society. J Invest Dermatol 1994; 102:695-9.
88. Holly EA, Kelly JW, Shpall SN, Chiu SH. Number of melanocytic nevi as a major risk factor for malignant melanoma. J Am Acad Dermatol 1987;17:459-68.
89. Bataille V, Newton-Bishop JA, Sasieni P, Swerdlow AJ, Pinney E, Griffiths K, et al. Risk of cutaneous melanoma in relation to the numbers, types, and sites of naevi. Br J Cancer 1996;73:1605-11.
90. Grulich A, Bataille V, Swerdlow A, Newton-Bishop JA, Cuzick J, Hersey P, et al. A case-control study of melanoma in New South Wales Australia. Int J Cancer 1996;67:485-91.
91. Greene MH. Rashomon and the Procrustean bed: a tale of dysplastic nevi. J Natl Cancer Inst 1991;83:1720-4.
92. Holly EA, Aston DA, Cress RD, Ahn DK, Kristiansen JJ. Cutaneous melanoma in women. II. Phenotypic characteristics and other host-related factors. Am J Epidemiol 1995;141: 934-42.
93. Swerdlow AJ, English J, MacKie RM, O'Doherty CJ, Hunter JA, Clark J. Benign naevi associated with high risk of melanoma (letter). Lancet 1984;2:168.
94. Vasen HFA, Bergman W, Van Haeringen A, Scheffer E, Van Slooten EA. The familial dysplastic nevus syndrome: natural history and the impact of screening on prognosis. A study of nine families in the Netherlands. Eur J Cancer Clin Oncol 1989;25:337-41.
95. Rigel DS, Rivers JK, Kopf AW, Friedman RJ, Vinokur AF, Heilman ER, et al. Dysplastic nevi. Markers for increased risk for melanoma. Cancer 1989;63:386-9.
96. Masri GD, Clark WH Jr, Guerry D IV, Halpern A, Thompson CJ, Elder DE. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. J Am Acad Dermatol 1990;22:1042-8.
97. MacKie RM, McHenry P, Hole D. Accelerated detection with prospective surveillance for cutaneous malignant melanoma in high-risk groups. Lancet 1993;341:1618-20.
98. Carey WP Jr, Thompson CJ, Synnestvedt M, Guerry D IV, Halpern A, Schultz D, et al. Dysplastic nevi as a melanoma risk factor in patients with familial melanoma. Cancer 1994; 74:3118-25.
99. Tiersten AD, Grin CM, Kopf AW, Gottlieb GJ, Bart RS, Rigel DS, et al. Prospective follow-up for malignant melanoma in patients with atypical-mole (dysplastic-nevus) syndrome. J Dermatol Surg Oncol 1991;17:44-8.
100. Halpern AC, Guerry D IV, Elder DE, Trock B, Synnestvedt M. A cohort study of melanoma in patients with dysplastic nevi. J Invest Dermatol 1993;100:346S-9S.
101. Kang S, Barnhill RL, Mihm MC Jr, Fitzpatrick TB, Sober AJ. Melanoma risk in individuals with clinically atypical nevi. Arch Dermatol 1994;130:999-1001.
102. Marghoob AA, Kopf AW, Rigel DS, Bart RS, Friedman RJ, Yadav S, et al. Risk of cutaneous malignant melanoma in patients with "classic" atypical-mole syndrome. A case-control study. Arch Dermatol 1994;130:993-8.
103. Schneider JS, Moore DH II, Sagebiel RW. Risk factors for melanoma incidence in perspective follow-up. The importance of atypical (dysplastic) nevi. Arch Dermatol 1994;130: 1002-7.
104. Kelly JW, Yeatman JM, Regalia C, Mason G, Henham AP. A high incidence of melanoma found in patients with multiple dysplastic nevi by photographic surveillance. Med J Aust 1997;167:191-4.
105. Ackerman AB. What naevus is dysplastic, a syndrome and the commonest precursor of malignant melanoma? A riddle and an answer. Histopathology 1988;13:241-56.
106. Slade J, Marghoob AA, Salopek TG, Rigel DS, Kopf AW, Bart RS. Atypical mole syndrome: risk factor for cutaneous malignant melanoma and implications for management. J Am Acad Dermatol 1995;32:479-94.
107. Clark WH. Tumour progression and the nature of cancer. Br J Cancer 1991;64:631-44
108. NIH Consensus Development Panel on Early Melanoma. Diagnosis and treatment of early melanoma. JAMA 1992; 268:1314-9.
109. Clark WH Jr, Evans HL, Everett MA, Farmer ER, Freeman RG, Graham JH, et al. Early melanoma: histologic terms. Am J Dermatopathol 1991;13:579-82.
110. Weinstock MA. Dysplastic nevi revisited (editorial). J Am Acad Dermatol 1994;30:807-10.
111. Mooi WJ: The dysplastic nevus. J Clin Pathol 1997;50: 711-5.
112. Greene MH. The prevention of cutaneous malignant melanoma: high-risk groups, chemoprevention, education and screening. In: Current research and clinical management of melanoma. Nathanson L, editor. Boston: Kluwer Academic Publishers, 1993:104-40.
113. Fraser MC, Goldstein AM, Tucker MA: The genetics of melanoma. Semin Oncol Nurs 1997;13:108-14.
114. Autier P, Doré JF, Gefeller O, Cesarini JP, Lejeune F, Koelmel KF, et al. Melanoma risk and residence in sunny areas. Br J Cancer 1997;76:1521-4.
115. Autier P, Doré JF, Lejeune F, Koelmel KF, Geffeler O, Hille P, et al. Cutaneous malignant melanoma and exposure to sunlamps or sunbeds. Int J Cancer 1994;58: 809-13.
116. Westerdahl J, Olsson H, Masbäch A, Ingvar C, Jonsson N, Brandt L, et al. Use of sunbeds or sunlamps and malignant melanoma in southern Sweden. Am J Epidemiol 1994;140: 691-9.
117. Greene MH, Young TI, Clark WH Jr. Malignant melanoma in renal transplant recipients. Lancet 1981;1:1196-9.
118. Tucker MA, Misfeldt D, Coleman N. Cutaneous malignant melanoma after Hodgkin's disease. Ann Intern Med 1985; 102:37-41.
119. Stern RS, Nichols KT, Vahava LH. Malignant melanoma in patients treated for psoriasis with methoxsalen and ultraviolet A radiation (PUVA). N Engl J Med 1997;336:1041-5.
120. Kopf AW, Rivers JK, Slue W. Photographs are useful for detection of melanoma in patients who have dysplastic nevi. J Am Acad Dermatol 1988;19:1132-4.
121. Slue W, Kopf AW, Rivers JK. Total body photographs of dysplastic nevi. Arch Dermatol 1988;124:1239-43.
122. Kornberg R, Ackerman AB. Pseudomelanoma - recurrent melanocytic nevus following partial surgical removal. Arch Dermatol 1975;111:1588-90.
123. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology - genetic testing for cancer susceptibility. J Clin Oncol 1996;14:1730-6.